Sarepta Therapeutics, Inc.
Every calculator, already run for SRPT
Open the full toolkit →You have the numbers on SRPT. Get the argument.
A written report on which of these readings actually decide the outcome for Sarepta Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
24 analysts covering SRPTAnalyst Price Target Disagreement for Sarepta Therapeutics, Inc.
Wall Street's bull case implies +110% from the current price; the bear case implies -72%. A 182% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and EL…
SRPT — frequently asked
Is SRPT a buy right now?
Wall Street's consensus rating on Sarepta Therapeutics, Inc. is Hold across 24 analysts, with a mean price target of $22.09 (+22% vs. the current $18.10). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is SRPT overvalued?
SRPT trades at — trailing earnings, against a DCF fair value of $8 per share. The current price implies 16% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is SRPT's next earnings date?
Sarepta Therapeutics, Inc. is next scheduled to report earnings around Nov 4, 2026. A full SRPT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Sarepta Therapeutics, Inc.?
Analysts covering Sarepta Therapeutics, Inc. (SRPT) range from a bear-case target of $5.00 to a bull-case high of $38.00, with a mean consensus target of $22.09 across 23 analysts. The spread of $33.00 (182% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Sarepta Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Sarepta Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SRPT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Sarepta Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.